Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplementary Material

Published byClara Cortés Modified over 5 years ago

Similar presentations

Presentation on theme: "Supplementary Material"— Presentation transcript:

1 Supplementary Material
Suppl. Fig. S1 HSF-1 knockdown cells show no difference in cell cycle distribution after combined Hsp90 inhibition and irradiation H1339 ctrl and HSF-1 k.d. cells were treated with 10nM NVP-AUY922 for 24h and irradiated with 6Gy. Cells were stained with PI to analyse cell cycle distribution 24h after irradiation.

2 Supplementary Material
Suppl. Fig. S2 HSF-1 knockdown and control cells show no difference in apoptosis induction after combined Hsp90 inhibition and irradiation A. Measurement of apoptosis induction 24h after irradiation by Annexin V and B. Caspase-3 staining of H1339 ctrl and HSF-1 k.d. cells treated with 10nM NVP-AUY922 for 24h following irradiation with 6Gy.

3 Supplementary Material
Supplementary Table S1: Summary of radiobiological parameters A. Loss of HSF-1 per se has no influence on radiosensitivity. D50, dose to reduce survival fraction to 50%. Sensitizing enhancement ratio (SER) = D50(irradiation ctrl)/D50(irradiation HSF-1 k.d.). B. Radiosensitizing effect of Hsp90 inhibition is much more pronounced in H1339 HSF-1 k.d. cells compared to control cells. SER ( D50(irradiation)/D50(irradiation + drug)) greater than 1.20 is indicative for radiosensitization (indicated in bold).

Download ppt "Supplementary Material"

Similar presentations

Fig. 4-1, p. 107. Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.
Supplemental Figure 1 actin MocksiRNA1siRNA2Mock Li Fraumeni (087)5C tankyrase1 100

Supplemental Figure 1 actin MocksiRNA1siRNA2Mock Li Fraumeni (087)5C tankyrase1 100
AB Supplementary Figure S1. (A) H1299 cells harboring pGC were transfected with I-SceI-expressing vector. Percentage of GFP + cells was assessed after.

AB Supplementary Figure S1. (A) H1299 cells harboring pGC were transfected with I-SceI-expressing vector. Percentage of GFP + cells was assessed after.
Supplementary Figure S1

Supplementary Figure S1
P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.
Fig. 11-1, p. 359. p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.
Table 6-1, p. 161. Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.
Supplementary Figures: Fig. 1, 2, and 3 show H1299 cells overexpressing Set7/9wt or H297A catalytic mutant and U2-OS, U2-OS Set7/9KD, and U2-OS Set7/9.

Supplementary Figures: Fig. 1, 2, and 3 show H1299 cells overexpressing Set7/9wt or H297A catalytic mutant and U2-OS, U2-OS Set7/9KD, and U2-OS Set7/9.
CLU inhibition using OGX-011 synergistically enhances Zol activity in osteosarcoma François Lamoureux, Marc Baud’huin, Benjamin Ory, Martin E. Gleave,

CLU inhibition using OGX-011 synergistically enhances Zol activity in osteosarcoma François Lamoureux, Marc Baud’huin, Benjamin Ory, Martin E. Gleave,
E2 GSCE2 bulkG7 GSCG7 bulk Mean SF4Gy (95% CI) 0.78 (0.72, 0.83) 0.56 (0.47, 0.64) 0.65 (0.57,0.72) 0.43 (0.34,0.51) T test of meansp = 0.001p = 0.002.

E2 GSCE2 bulkG7 GSCG7 bulk Mean SF4Gy (95% CI) 0.78 (0.72, 0.83) 0.56 (0.47, 0.64) 0.65 (0.57,0.72) 0.43 (0.34,0.51) T test of meansp = 0.001p =
Supplementary Figure 1A-B A H1299 RH1299 0 15 30 45 60 0 45 80 160 200 LC3-I / II P-GSK-3 (Ser21/9) GSK-3α/β β-actin β-catenine P-GSK-3 (Tyr279/216) B.

Supplementary Figure 1A-B A H1299 RH LC3-I / II P-GSK-3 (Ser21/9) GSK-3α/β β-actin β-catenine P-GSK-3 (Tyr279/216) B.
A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in.

A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in.
Supplementary Figure 1 Supplementary Figure 1. Kaplan–Meier estimates of recurrence-free survival (RFS) according to the expression of every ten mRNA/lncRNA.

Supplementary Figure 1 Supplementary Figure 1. Kaplan–Meier estimates of recurrence-free survival (RFS) according to the expression of every ten mRNA/lncRNA.
Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)

Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)
G1 synchronous cells released at T = 0

G1 synchronous cells released at T = 0
Mel501 Supplementary 1A Caspase 8 activity % 24h Caspase 9 activity %

Mel501 Supplementary 1A Caspase 8 activity % 24h Caspase 9 activity %
Date of download: 10/24/2017 Copyright © ASME. All rights reserved.

Date of download: 10/24/2017 Copyright © ASME. All rights reserved.
Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1α Cell Physiol Biochem 2014;33:37-51.

Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1α Cell Physiol Biochem 2014;33:37-51.
0 Gy NSC NSC 5 Gy NSC NSC NSC NSC NSC NSC NSC NSC NSC NSC NSC NSC

0 Gy NSC NSC 5 Gy NSC NSC NSC NSC NSC NSC NSC NSC NSC NSC NSC NSC
Ctrl IR, 2h G2 P53 Ser15 S G1 G2 S G1 Figure S1. The bivariate (phospho-p53 Ser15 vs DNA content) distribution of control and irradiated with 6 Gy mESCs.

Ctrl IR, 2h G2 P53 Ser15 S G1 G2 S G1 Figure S1. The bivariate (phospho-p53 Ser15 vs DNA content) distribution of control and irradiated with 6 Gy mESCs.

Similar presentations

Ads by Google